These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 36092887)

  • 21. Construction of cuproptosis-related gene signature to predict the prognosis and immunotherapy efficacy of patients with bladder cancer through bioinformatics analysis and experimental validation.
    Liu Z; Zhu F; Zhang P; Qian B; Liu W; Xiao Y; Chen N; He Q; Xiao J
    Front Genet; 2022; 13():1074981. PubMed ID: 36506302
    [No Abstract]   [Full Text] [Related]  

  • 22. Identification of cuproptosis-related subtypes and development of a prognostic signature in colorectal cancer.
    Huang Y; Yin D; Wu L
    Sci Rep; 2022 Oct; 12(1):17348. PubMed ID: 36253436
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pan-cancer analysis of cuproptosis-promoting gene signature from multiple perspectives.
    Ma J; Gong B; Zhao Q
    Clin Exp Med; 2023 Dec; 23(8):4997-5014. PubMed ID: 37318649
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Molecular subtypes and tumor microenvironment infiltration signatures based on cuproptosis-related genes in colon cancer.
    Luo H; Zhang Q; Liu X; Luo Y; Jiang X; Wang C; Chen B; He Q; Zhang Y; Shu O; Dai P; He C
    Front Oncol; 2023; 13():999193. PubMed ID: 37274263
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comprehensive analysis of cuproptosis-related lncRNAs to predict prognosis and immune infiltration characteristics in colorectal cancer.
    Zhu Z; Zhao Q; Li S; Weng J; Guo T; Zhu C; Xu Y
    Front Genet; 2022; 13():984743. PubMed ID: 36467996
    [No Abstract]   [Full Text] [Related]  

  • 26. Identification of cuproptosis-related long non-coding ribonucleic acid signature as a novel prognosis model for colon cancer.
    Xu R; Wu X; Du A; Zhao Q; Huang H
    Am J Cancer Res; 2022; 12(11):5241-5254. PubMed ID: 36504883
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A novel cuproptosis-related lncRNA nomogram to improve the prognosis prediction of gastric cancer.
    Feng A; He L; Chen T; Xu M
    Front Oncol; 2022; 12():957966. PubMed ID: 36106123
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A novel signature to guide osteosarcoma prognosis and immune microenvironment: Cuproptosis-related lncRNA.
    Yang M; Zheng H; Xu K; Yuan Q; Aihaiti Y; Cai Y; Xu P
    Front Immunol; 2022; 13():919231. PubMed ID: 35967366
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Identification of a Novel Cuproptosis-Related Gene Signature and Integrative Analyses in Thyroid Cancer.
    Huang J; Shi J; Wu P; Sun W; Zhang D; Wang Z; Ji X; Lv C; Zhang T; Zhang P; Zhang H
    J Clin Med; 2023 Mar; 12(5):. PubMed ID: 36902801
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A novel defined cuproptosis-related gene signature for predicting the prognosis of lung adenocarcinoma.
    Zhang H; Shi Y; Yi Q; Wang C; Xia Q; Zhang Y; Jiang W; Qi J
    Front Genet; 2022; 13():975185. PubMed ID: 36046242
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The role of a cuproptosis-related prognostic signature in colon cancer tumor microenvironment and immune responses.
    Xu C; Liu Y; Zhang Y; Gao L
    Front Genet; 2022; 13():928105. PubMed ID: 36313449
    [No Abstract]   [Full Text] [Related]  

  • 32. A Newly Established Cuproptosis-Associated Long Non-Coding RNA Signature for Predicting Prognosis and Indicating Immune Microenvironment Features in Soft Tissue Sarcoma.
    Han J; Hu Y; Liu S; Jiang J; Wang H
    J Oncol; 2022; 2022():8489387. PubMed ID: 35847354
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cuproptosis-Associated lncRNA Establishes New Prognostic Profile and Predicts Immunotherapy Response in Clear Cell Renal Cell Carcinoma.
    Xu S; Liu D; Chang T; Wen X; Ma S; Sun G; Wang L; Chen S; Xu Y; Zhang H
    Front Genet; 2022; 13():938259. PubMed ID: 35910212
    [No Abstract]   [Full Text] [Related]  

  • 34. Unveiling a cuproptosis-related risk model and the role of FARSB in hepatocellular carcinoma.
    Duan J; Zhang X; Xu J; Liu J; Zhao H
    Heliyon; 2024 Jun; 10(12):e32289. PubMed ID: 38975141
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The prognostic value and immune landscape of a cuproptosis-related lncRNA signature in head and neck squamous cell carcinoma.
    Li YJ; Li HY; Zhang Q; Wei SL
    Front Genet; 2022; 13():942785. PubMed ID: 35942287
    [No Abstract]   [Full Text] [Related]  

  • 36. Role of cuproptosis-related gene in lung adenocarcinoma.
    Liu Y; Lin W; Yang Y; Shao J; Zhao H; Wang G; Shen A
    Front Oncol; 2022; 12():1080985. PubMed ID: 36620594
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A cuproptosis-related genes signature associated with prognosis and immune cell infiltration in osteosarcoma.
    Yang W; Wu H; Tong L; Wang Y; Guo Q; Xu L; Yan H; Yin C; Sun Z
    Front Oncol; 2022; 12():1015094. PubMed ID: 36276092
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Identification of cuproptosis-related patterns and construction of a scoring system for predicting prognosis, tumor microenvironment-infiltration characteristics, and immunotherapy efficacy in breast cancer.
    Li W; Zhang X; Chen Y; Pang D
    Front Oncol; 2022; 12():966511. PubMed ID: 36212436
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The cuproptosis related genes signature predicts the prognosis and correlates with the immune status of clear cell renal cell carcinoma.
    Sun P; Xu H; Zhu K; Li M; Han R; Shen J; Xia X; Chen X; Fei G; Zhou S; Wang R
    Front Genet; 2022; 13():1061382. PubMed ID: 36531222
    [No Abstract]   [Full Text] [Related]  

  • 40. Construction and comprehensive analysis of a curoptosis-related lncRNA signature for predicting prognosis and immune response in cervical cancer.
    Liu L; Zheng J; Xia H; Wu Q; Cai X; Ji L; Sun Y
    Front Genet; 2023; 14():1023613. PubMed ID: 36777734
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.